Alteration of the E-cadherin/β-Catenin Complex Predicts Poor Response to Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor (EGFR-TKI) Treatment

By Yoo Seol   Kim Yu   Kim Hyojin   Jin Yan   Sun Ping-Li   Jheon Sanghoon   Lee Jong   Chung Jin-Haeng  

Annals of Surgical Oncology, Vol. 20, Iss. 3, 2013-12 ,pp. : 545-552

Springer Publishing Company

Access to resources Recommend Favorite

Dermatological reactions to the multitargeted tyrosine kinase inhibitor sunitinib

By Rosenbaum S.  

Supportive Care in Cancer, Vol. 16, Iss. 6, 2008-06 ,pp. : 557-566

Springer Publishing Company

Access to resources Recommend Favorite

Switching to second‐generation tyrosine kinase inhibitor improves the response and outcome of frontline imatinib‐treated patients with chronic myeloid leukemia with more than 10% of BCR‐ABL/ABL ratio at 3 months

By  

Cancer Medicine, Vol. 4, Iss. 7, 2015-07 ,pp. : 995-1002

John Wiley & Sons Inc

Access to resources Recommend Favorite

SAR103168: a tyrosine kinase inhibitor with therapeutic potential in myeloid leukemias

By Bourrié Bernard  

Leukemia and Lymphoma, Vol. 54, Iss. 7, 2013-07 ,pp. : 1488-1499

Informa Healthcare

Access to resources Recommend Favorite

AZD3409 inhibits the growth of breast cancer cells with intrinsic resistance to the EGFR tyrosine kinase inhibitor gefitinib

By Maiello Monica   D’Alessio Amelia   Luca Antonella   Carotenuto Adele   Rachiglio Anna   Napolitano Maria   Cito Letizia   Guzzo Antonella   Normanno Nicola  

Breast Cancer Research and Treatment, Vol. 102, Iss. 3, 2007-05 ,pp. : 275-282

Springer Publishing Company

Access to resources Recommend Favorite